Showing results (151-160 of 170) with videos related to
Sort By:
Pageof 17
Blood|August 29, 2013
MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium ProgramZijun Y Xu-Monette, Michael B Møller, Alexander Tzankov, et al.Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|November 7, 2015
Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOPZijun Y Xu-Monette, Bouthaina S Dabaja, Xiaoxiao Wang, et al.Neoplasia (New York, N.Y.)|May 8, 2018
Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell LymphomaXiaoxiao Wang, Xin Cao, Ruifang Sun, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 14, 2026
Rituximab Maintenance Added to Ibrutinib-Containing Therapy in Younger, Untreated Patients With Mantle Cell Lymphoma: Results From the TRIANGLE TrialMarco Ladetto, Katja Gutmair, Rita Tavarozzi, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 2, 2016
Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell LymphomaZijun Y Xu-Monette, Qipan Deng, Ganiraju C Manyam, et al.Blood|October 26, 2016
Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphomaZijun Y Xu-Monette, Ling Li, John C Byrd, et al.Research Square|January 27, 2025
Prognostic gene expression and microRNA profiling signatures and genetic alterations in primary testicular diffuse large B-cell lymphomaKen Young, Wen-Yu Shi, Zijun Xu-Monette, et al.Blood|January 25, 2013
CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program StudyShimin Hu, Zijun Y Xu-Monette, Aarthi Balasubramanyam, et al.Oncotarget|June 24, 2015
Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma--is it necessary?Chi Young Ok, Qing Ye, Ling Li, et al.Blood|March 2, 2013
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium ProgramShimin Hu, Zijun Y Xu-Monette, Alexander Tzankov, et al.Pageof 17